MedPlus Reports 21.8% Revenue Growth in Q1 FY27; Margin Pressure Weighs on Profitability

What Happened ?

key details

Business Performance:

MedPlus sustained strong business momentum during Q1 FY27, driven by higher customer demand, continued pharmacy expansion and stable performance from mature stores. The company remained on track with its growth strategy despite facing pressure on operating margins during the quarter. 

Key Business Highlights:

• Consolidated revenue grew 21.8% YoY to ₹18,796 million.
• Revenue achieved 99% of the company’s Annual Operating Plan (AOP).
• Sales from stores operating for more than 12 months increased 15.3% YoY, indicating healthy same-store business growth.
• The company continued strengthening its omnichannel pharmacy model across both physical stores and digital platforms.

Store Network Expansion:

Store expansion remained one of MedPlus’ key growth drivers during the quarter, with the company continuing to deepen its presence across India through both company-operated and franchise stores.

Expansion Highlights

• 222 gross stores were opened during Q1 FY27.
• 146 net stores were added after accounting for closures.
• 131 franchise stores were added during the quarter.
• The total pharmacy network increased to 5,476 stores.
• Operations now span 13 states, 1 Union Territory, and 850+ cities and towns. 

Operating Performance:

While revenue remained strong, operating profitability was affected by changes in product mix and business composition.

Operational Developments

• Gross margin declined to 24.5% from 26.1% in the corresponding quarter last year.
• The reduction was primarily attributed to:
  • Lower contribution from private label products.
  • Higher contribution from the franchise business, which operates at relatively lower margins.
• Company Operating EBITDA margin moderated to 3.5%.
• Pharmacy Operating EBITDA margin stood at 3.2% during the quarter.

Mature Store Economics:

The company’s mature stores continued to demonstrate healthy operating efficiency and profitability.

Mature Store Performance

• Stores operating for more than 12 months generated:
  • 15.3% YoY revenue growth.
  • 10.4% Store-Level EBITDA Margin.
  • 63.0% Store-Level Operating ROCE.
• These metrics indicate that mature stores continue to deliver strong returns while supporting the economics of the company’s expansion strategy.

Liquidity & Cash Generation:

MedPlus maintained a healthy balance sheet and continued generating strong operating cash flows during the quarter.

Financial Strength

• Operating Cash Flow amounted to ₹1,252 million.
• Operating Cash Flow represented 192.2% of Company Operating EBITDA.
• Cash and Bank Balance stood at ₹6,219 million at the end of the quarter, providing financial flexibility to support future expansion and working capital requirements. 

Strategic Focus:

The company continues to pursue long-term growth by expanding its pharmacy footprint while improving customer accessibility and operational efficiency.

Strategic Priorities

• Accelerate pharmacy network expansion across existing and new markets.
• Improve penetration of higher-margin private label products.
• Enhance productivity of newly opened stores.
• Strengthen the omnichannel healthcare ecosystem.
• Maintain disciplined capital allocation while supporting long-term profitable growth. 

Note:

• MedPlus delivered another quarter of strong operational execution, supported by robust revenue growth, rapid store expansion and healthy mature-store performance.
• Although lower private label contribution and franchise mix affected margins during Q1 FY27, the company’s strong cash generation, expanding retail footprint and scalable business model continue to support its long-term growth strategy.

Risk Analysis

Summary:

• MedPlus delivered strong revenue growth and continued expanding its retail footprint during Q1 FY27. However, the quarter reflected pressure on profitability as gross margins and operating EBITDA margins declined due to a lower contribution from higher-margin private label products and an increasing share of franchise business. While cash generation remained healthy, sustaining margins alongside rapid expansion will be an important area for investors to monitor.

Key Risks:

• Margin Compression: Gross margin declined to 24.5%, down 160 basis points YoY and 200 basis points QoQ, reflecting an unfavorable product and business mix.
• Private Label Contribution: A 1.5% YoY decline in private label sales reduced the contribution of higher-margin products, impacting overall profitability.
• Operating Profitability: Company Operating EBITDA margin fell to 3.5%, while Pharmacy Operating EBITDA margin declined to 3.2%, indicating weaker operating leverage despite higher revenue.
• Expansion Execution: The addition of 146 net stores during the quarter requires successful integration and ramp-up to maintain long-term returns and operational efficiency.
• Competitive Environment: Continued competition in organized pharmacy retail and omnichannel healthcare may place pressure on pricing, customer acquisition and margins.
• Store Maturity: Nearly 27% of the pharmacy network is less than two years old, meaning a significant portion of stores are still progressing toward mature profitability.

Worst Case:

• If gross margins continue to decline because of lower private label contribution, increasing franchise mix or competitive pricing pressures, MedPlus could experience slower earnings growth despite continued revenue expansion. Additionally, if newly opened stores take longer than expected to achieve mature profitability, returns on expansion investments may moderate.

Risk Level: Medium

Company Commentary

According to the investor presentation, MedPlus continues to focus on expanding its pharmacy network while strengthening its omnichannel healthcare platform and improving long-term profitability.

Key strategic priorities highlighted by the company include:

• Continue expanding existing clusters while developing new markets across its operating regions.
• Leverage its in-house technology platform to strengthen the omnichannel business and extend less than two-hour delivery to additional locations.
• Increase customer retention through integrated online and offline services.
• Expand the contribution of private label products, particularly in chronic and sub-chronic pharmaceutical categories as well as FMCG and wellness products.
• Continue disciplined store expansion supported by strong operating cash flows and a healthy cash position.